Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 3, 2001, Pages 292-298

  Thijssen, Henk H W ^a   Drittij, Marie José ^a   Vervoort, Lily M T ^a   De Vries Hanje, Johanna C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; CYTOCHROME P450 2C9; DRUG METABOLITE;

ADULT; ANTICOAGULATION; ARTICLE; CASE REPORT; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG SENSITIVITY; FIRST PASS EFFECT; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; MALE; PRIORITY JOURNAL; STEREOCHEMISTRY; URINALYSIS;

ACENOCOUMAROL; ADOLESCENT; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG HYPERSENSITIVITY; EXONS; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0034834563     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.117936     Document Type: Article

References (27)

1. Pharmacokinetics of the enantiomers of acenocoumarol in man
2. Lack of effect of cimetidine on pharmacodynamics and kinetics of R- and S-acenocoumarol
3. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes
4. Allelic variants of human cytochrome P450 2C9: Baculovirus mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
5. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
6. 359 variants: Enzyme kinetic study with seven substrates
7. Genetic analysis of the human cytochrome P450 CYP2C9 locus
8. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population
9. Human P450 metabolism of warfarin
10. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients under, going anticoagulation therapy
11. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and the risk of bleeding complications
12. Genetic association between sensitivity to warfarin and expression of CYP2C9*3
13. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: Catalytic activities of cDNA-expressed CYP2C9, its leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes
14. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol
15. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese
16. Genetic analysis of CYP2C9 polymorphism in a Japanese population
17. Cimetidine-nicoumalone interaction in man: Stereochemical considerations
18. No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics
19. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
20. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
21. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children
22. A physiological approach to hepatic drug clearance
23. No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics
24. Lack of effect of ponsinomycin on the pharmacokinetics of nicoumalone enantiomers
25. Stereoselective interaction between piroxicam and acenocoumarol
26. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
27. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174